Oaktree Acquisition III Life Sciences Corp (OACC) FinancialsOACCFinancialOaktree Acquisition III Life Sciences Corp

Evaluating the bottom line, Oaktree Acquisition III Life Sciences Corp maintains a gross margin of N/A. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at N/A, while the net margin is N/A. These profitability ratios, combined with a Return on Equity (ROE) of 3.65%, provide a clear picture of how effectively OACC converts its operational activities into shareholder value.

In the context of the broader market, OACC competes directly with industry leaders such as NTWO and DMAA. With a market capitalization of $265.00M, it holds a leading position in the sector. When comparing efficiency, OACC's gross margin of N/A stands against NTWO's N/A and DMAA's N/A. Such benchmarking helps identify whether Oaktree Acquisition III Life Sciences Corp is trading at a premium or discount relative to its financial performance.

The company has shown fluctuations in net income, with a notable negative net income of -48095.00 USD in Q3 2024, but it has rebounded with positive net income in subsequent quarters, reaching 1966742.00 USD in Q3 2025. The EPS has also improved from -0.00 in Q3 2024 to 0.08 in Q2 2025, indicating potential for growth.